- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Nanexa AB: Forge Nano and Nanexa Enter Joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell Long-Acting Injectable Medicines | 142 | GlobeNewswire (Europe) | Collaboration intended to develop large-scale, GMP-compliant ALD manufacturing equipment supporting Nanexa's broad portfolio of proprietary and partnered PharmaShell® programs.
DENVER and UPPSALA, SWEDEN... ► Artikel lesen | |
| 27.08. | Nanexa AB Q2 Loss Climbs | 3 | RTTNews | ||
| 12.05. | Nanexa AB: Bulletin from the Annual General Meeting of Nanexa AB | 320 | GlobeNewswire (Europe) | The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 12, 2026, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.
The... ► Artikel lesen | |
| 29.04. | Nanexa AB: Nanexa publishes interim report for January-March 2026 | 666 | GlobeNewswire (Europe) | Opened the year with strong preclinical results for once-monthly and quarterly dosing of semaglutide
Significant events during the first quarter of 2026In January, Nanexa announced breakthrough preclinical... ► Artikel lesen | |
| 28.04. | Nanexa AB: Nanexa resolves on set-off of outstanding loan | 194 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA,... ► Artikel lesen | |
| 19.03. | Nanexa AB: Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell | 462 | GlobeNewswire (Europe) | Nanexa's atomic layer deposition (ALD)-based PharmaShell® platform enables an unprecedented pharmacokinetic profile for semaglutide, also supporting the potential for once-quarterly administration.New... ► Artikel lesen | |
| NANEXA Aktie jetzt für 0€ handeln | |||||
| 19.02. | Nanexa AB: Nanexa publishes year-end report and Q4 report 2025 | 282 | GlobeNewswire (Europe) | The year ended strongly with an important milestone; the license and option agreement with Moderna, which is an important validation of our technology and has created favourable conditions for 2026... ► Artikel lesen | |
| 27.01. | Nanexa AB: Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation | 480 | GlobeNewswire (Europe) | Nanexa's atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.Significantly smoother plasma concentration curve could mitigate... ► Artikel lesen | |
| 10.12.25 | Nanexa AB: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell-based products | 525 | GlobeNewswire (Europe) | The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments... ► Artikel lesen | |
| 06.11.25 | Nanexa AB: Nanexa publishes interim report for January-September 2025 | 304 | GlobeNewswire (Europe) | We have progressed with the optimization of our GLP-1 formulations, extended an existing commercial partnership, received approval for a PharmaShell patent application in Japan and submitted three new... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 49,550 | +1,06 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| MERCK KGAA | 133,15 | +0,41 % | Merck strengthens commitment to China with rare disease awareness initiative | ||
| JAGUAR HEALTH | 34,460 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenDE000A2YNT30 Alzchem Group AG 16.09.2026 DE000A41YHG1 Alzchem Group AG 17.09.2026 Tausch 1:1AU0000090060 Europa Metals... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 57,09 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| NOVO NORDISK | 34,680 | -0,34 % | Novo-Aktie: Am Montag müssen diese 3 Antworten kommen! | Die Novo-Aktie hat sich am Freitag um +1,4% erholt. Der wirklich wichtige Termin folgt jedoch am Montag: Beim Kapitalmarkttag in London will das Management neue strategische Ziele präsentieren und über... ► Artikel lesen | |
| CHEPLAPHARM | 102,26 | 0,00 % | M&A-Deals: Cheplapharm, Vossloh, Heidelberg Materials | ||
| IM CANNABIS CORP | 4,100 | -0,97 % | Morning Market Movers: Top Ships, IM Cannabis, GD Culture Group, Solidion Technology See Big Swings | BEIJING (dpa-AFX) - At 6:45 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 17,440 | -0,11 % | Generate Biomedicines auf der H.C. Wainwright Konferenz: Plattform-Strategie im Fokus | ||
| AQUESTIVE THERAPEUTICS | 4,945 | -0,10 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm (dibutepinephrine) Sublingual Film | Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable... ► Artikel lesen | |
| APNIMED | 25,560 | 0,00 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| ELI LILLY | 1.028,20 | +0,53 % | Umsatzschub zündet!: Rekordumsatz! Dieser Micro-Cap übertrifft nach acht Monaten bereits das gesamte Vorjahr | ||
| PFIZER | 24,405 | +0,04 % | Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? | ||
| SCHOTT PHARMA | 24,000 | +2,13 % | Aktien Frankfurt: Dax macht Verluste wett - Ölpreis und Anleiherenditen im Fokus | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt hat sich am Dienstagnachmittag von seinen Anfangsverlusten vollständig erholt. Eine leichte Entspannung bei den Ölpreisen und bei den Anleiherenditen... ► Artikel lesen | |
| DERMAPHARM | 39,750 | +2,45 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| OMNIAB | 4,920 | 0,00 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANEXA AB finden Sie auf Wallstreet Online.